Tumor EGFR copy number did not turn out as a predictive biomarker for the efficacy of cetuximab plus platinum/5-FU as first-line therapy for patients with R/M HNSCC (Licitra et al., 2011). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.